Seven projects led by research teams from the U.S. and Europe have been announced as the recipients of the latest round of Lupus Research Alliance (LRA) Lupus Innovation Award (LIA) grants, which can total up to $300,000. The awards provide support — up to $150,000 annually for two…
JW Therapeutics has received approval from Chinese authorities to open a clinical trial of its CAR T-cell therapy, relmacabtagene autoleucel (relma-cel), in systemic lupus erythematosus (SLE) patients with moderate-to-severe and treatment-resistant active disease. Although not approved for SLE or other autoimmune disorders, relma-cel is available under the…
Viral infections with cytomegalovirus, known as CMV, are highly prevalent in children with systemic lupus erythematosus (SLE), and are linked to high disease activity and poor outcomes, a study in China reports. Given that anti-CMV treatment can reduce disease activity and flares, the virus’ early identification and treatment…
Over 18 months, the approved therapy Lupkynis (voclosporin) lessened inflammation and prevented further kidney damage in systemic lupus erythematosus (SLE) patients with active lupus nephritis, without any signs of kidney-related toxicity seen with similar treatments. New top-line data show participants in the Lupkynis treatment arm of the now…
The U.S. Food and Drug Administration (FDA) has cleared a Phase 1/2 clinical trial to test CABA-201, Cabaletta Bio’s investigational CAR T-cell therapy, in people with systemic lupus erythematosus (SLE) with or without kidney involvement. Cabaletta asked to launch the trial in the form of an investigational new…
The Lupus Research Alliance (LRA) has convened a public-private consortium to bring together the U.S. Food and Drug Administration (FDA) and key stakeholders to overcome scientific hurdles in lupus and advance new personalized treatments. The patient-focused Lupus Accelerating Breakthroughs Consortium (Lupus ABC) will also be made up…
Treatment with upadacitinib led to a significant reduction in disease activity for people with moderate-to-severe systemic lupus erythematosus (SLE) in a Phase 2 clinical trial, according to top-line results announced by its developer, AbbVie. Based on these positive results, AbbVie now is planning to advance upadacitinib to Phase 3 clinical…
A type of anti-DNA autoantibodies that also block an enzyme called DNase1L3 may cause more harm to people with systemic lupus erythematosus (SLE) than those that only bind to genetic material, a study has found. These results, the researchers say, shed new light on the origin of SLE, the…
Progentec Diagnostics has partnered with GSK to launch PROACTIVE, a study to identify people at risk of developing lupus. The study seeks to help with the early detection and diagnosis of lupus, which is critical for its effective treatment and management. Participants will be guided through…
Organ damage is associated with a 1.49-times higher odds of having severe cognitive dysfunction in people with systemic lupus erythematosus (SLE), a new study reports. Organ damage was also associated with worse performance in multiple neuropsychological domains, such as working memory, processing speed, and complex attention. By contrast, the…